CHEMOTHERAPY and supportive treatment in acute myeloblastic leukaemia (AML) has improved to the extent of achieving complete remission in over half the patients in a number of series (Spiers, 1972) . However, the length of remissions is disappointingly short and, while half of first remissions may exceed a year, only a handful of patients are alive 3 years after presentation. This situation has provided a strong impetus to find improved methods of sustaining remission in this disease. Immunotherapy is among the approaches tried, and some encouraging results have been reported (Powles et al., 1973; Gutterman et at., 1974; Vogler and Chan, 1974) . The data from the St Bartholomew's Hospital study (Powles et at., 1973) are of particular interest, for this trial included concurrent controls treated with chemotherapy. The immunotherapy patients received the same chemotherapy, but were also given 109 allogeneic irradiated cryopreserved leukaemic myeloblasts and live BCG weekly after achieving remission.
One of the rationales for including allogeneic myeloblasts in immunotherapy is that these might share antigens with the patients' own leukaemic cells. However, it should be stressed that the existence of common tumour-specific antigens in acute myeloblastic leukaemia has not yet been proved, despite considerable work on this topic. Autologous myeloblasts have been shown to produce delayed-hypersensitivitytype skin responses at some time in the course of the disease in most patients (Baker et al., ] .974b), and can also stimulate blastogenesis of autologous lymphocytes (Powles et al., 1971) . Although these data are consistent with the presence on the myeloblast of an antigen foreign to the autologous host, these studies do not demonstrate that the antigens on different myeloblasts are similar.
Various attempts have been made to produce a xenogeneic serum which will recognize myeloblastic-leukaemia-specific antigen. Baker, Ramachandar and Taub (1974a) in mice, and Mann, Halterman and Leventhal (1974) in rabbits, have produced sera which they regarded as probably myeloblast-specific. Seigler et al. (1975) , working with chimpanzees, have not been able to produce sera reacting with all myeloblasts, and suggest that these more closely related animals may be able to recognize differences in the surface structure of human leukaemic myeloblasts to which lower animals are " blind ". They have produced antisera which react with groups of myeloblasts, though not with all. All these studies have used absorption with normal human tissue to produce sera thought to be more reactive against myeloblasts than normal tissues, but critical appraisal of these data leaves some doubt as to whether they conclusively demonstrate tumour-specific antigens.
Hersey et al. (1973) previously described a high incidence of antibody which was cytotoxic against allogeneic myeloblasts, in AML patients receiving immunotherapy. These authors pointed out that this activity could have been directed against normal transplantation antigens. This study seeks to assess the specificity of such antibodies in sera from patients undergoing immunotherapy in the 6th Medical Research Council trial of treatment in acute myeloblastic leukaemia.
PATIENTS
All material studied was from patients in the Medical Research Council's 6th trial of therapy in AML. The treatment protocol was essentially that used in the St Bartholomew's Hospital 3rd trial (Powles et al., 1973) . After induction of remission, patients were given one further 5-day course of chemotherapy followed by weekly injections of 109 irradiated allogeneic cryopreserved myeloblasts in divided doses in 3 limbs subcutaneously and intradermally. Live BCG (Glaxo) was inoculated into the fourth limb by Heaf technique. Each limb was used for the BCG administration in rotation. Maintenance chemotherapy was given for 5 days during each 4th week for the first 12 months of remission.
METHODS (i) Target cells
The leukaemic myeloblasts used in this study were collected from patients entered in the 6th MRC trial who had high peripheral white cell counts at presentation. In a few cases, the myeloblasts were collected using a continuous-flow cell separator (International Business Machines) at the Royal Marsden Hospital or Manchester Royal Infirmary. The blood was collected into acid citrate dextrose and allowed to sediment at 1 g for 1-2 h. The supernatant leucocyte-rich plasma above the red cells was collected and centrifuged. The cell residue was resuspended in autologous plasma or Hepesbuffered Eagle's basal medium (BME) with 10% foetal bovine serum (FBS). After addition of 10% dimethyl sulphoxide the cells were frozen at -1°C per minute to about -60°C and then stored over liquid N2.
The myeloblasts used for the major part of this work were chosen from those in store at Oxford, because of their availability in suitable numbers, viability and favourable labelling characteristics. None of the panel myeloblasts were derived from, or had been used for immunization of any of the patients whose sera were tested. Cytocentrifuge preparations were made of aliquots of all samples used, or from samples from the same batch. In all cases, at least 90% of the cells in the preparations were judged on morphological grounds to be myeloblasts: the remainder were lymphocytes. The myeloblasts were thawed rapidly and diluted drop by drop over about 10 min with 10% FBS in saline at 30°C. After centrifugation, approximately 2-3 x 107 myeloblasts were suspended in 0 5 ml BME + FBS with 100 ,uCi 51Cr-chromate (Radiochemical Centre, Amersham) and placed in a 30-ml universal container. After incubation at 37°C for 2 h, 20 ml BME was added and 1P5 ml FBS carefully layered under the suspension. After centrifugation, the supernatant was removed and the myeloblasts resuspended at a concentration to give approximately 2 x 104 cells per well. In the labelling conditions used by us the incorporation of sodium [51Cr] chromate by myeloblasts is somewhat greater than that by lymphocytes (MacLennan, Gale and Wood, 1975) . It can therefore be assumed that well over 90% of label in these preparations was in myeloblasts.
Lymphocytes to be used as targets were separated from heparinized blood of normal volunteers by Ficoll-Triosil gradient. After 2 washes in BME the labelling procedure used for myeloblasts was followed.
(ii) Test sera Sera from patients receiving immunotherapy were collected from fresh, defibrinated blood and stored at -12°C until used. Dilutions of 1/5, 1/20, 1/80, 1/320 and 1/1280 were used for complement-induced lysis. Dilutions of 1/10, 1/50, 1/250, 1/1250 and 1/a were used for assays of antibody-induced lymphocyte-dependent cytotoxicity (K-celldependent cytotoxicity or KDC). Two rat sera known to have cytotoxic activity against most myeloblasts were included in each assay as a positive control. They were prepared by pooling the sera of 3 rats, bled out 14 days after i.p. injection of 5 x 107 human leukaemic myeloblasts.
(iii) Cytotoxic mediators (a) Complement.-Fresh normal human serum was frozen in liquid N2. Aliquots of this were thawed for use as a complement source. More than one pool was used but all had good lytic activity against myeloblasts sensitized with positive control sera. It was used in a final concentration of 20%.
(b) Lymphocytes (K cells).-For KDC assays, lymphocytes were collected from defibrinated normal human blood by gelatine sedimentation. After centrifugation and one wash in BME, the lymphocytes were resuspended and used at 3.5 x 105/well. Several normal volunteers participated but only one donor was involved in testing each myeloblast against the whole batch of sera.
(iv) Test procedure All experiments were carried out in sterile Biocult 250-,ul round-bottomed-well microplates with 96 wells. All experiments were carried out in duplicate, with a final volume of 200 ,tl per well. The basic medium used was BME, supplemented with glutamine, non-essential aminoacids and penicillin and streptomycin. FBS was not added except at the stage of labelling. As far as possible, the medium was used at 37°C at all times.
Labelled target cells, test serum and mediators were mixed in the concentration and volumes indicated above and incubated at 37°C. Complement assays were incubated for 2-h and KDC assays for 6 h. After incubation the plates were centrifuged at 100 g for 5 min and 150 ,ul of supernatant was pipetted off and retained for counting.
To measure total 51Cr per well, 4 aliquots of the target-cell mixture containing 2 x 104 cells were retained for separate counting. Gamma emission of the samples was counted, using a Wallac automatic well scintillation counter. The percentage chromium release (CR) was calculated by the formula: CR-(133 x S -background) x 100 (T -background) where S = ct/s of supernatant. T = total well ct/s (mean counts of aliquots of myeloblast mixture). background= background irradiation in ct/s (taken to be a constant, 0 9 ct/s). are illustrated in Fig. 1 , where the cytotoxicity of a positive, possible and negative serum from one patient against one myeloblast in the KDC assay is illustrated. If cytotoxic antibody against a myeloblast-specific antigen were being produced regularly in response to the form of immunotherapy under study, it would be expected that several sera cytotoxic to all of the panels of myeloblasts would have been detected. In fact, in no case was a serum able to damage all of the myeloblasts in a panel, and few could produce cytotoxicity to 4 myeloblasts. Comparison of the pattern of occurrence of antibodyinducing complement-mediated and KDC lysis shows a tendency for complement lytic capacity to occur both early and late in the course of immunotherapy and not necessarily to persist once present. In contrast, KDC lytic capacity occurs with increasing frequency with increased duration of treatment, and once present is more constant. When the number of positive responses produced by a serum is related to the number of different myeloblasts which had been used to immunize the donor of the serum, a significant correlation is seen for the KDC assay, but not for the complement lytic assay (Fig.4) . immunization of each patient until supplies were exhausted and then immunization with a second or third myeloblast was started, the effect of increased numbers of immunizing myeloblasts cannot be separated from the effect of greater duration of immunotherapy. There was little or no correlation between positive results in the 2 assays for individual sera, suggesting that these assays were measuring a partially or wholly different range of antibodies and/or antigens.
3. The effect of cryopreservation of myeloblasts on sensitivity to antibody-induced Iysis A comparison was made of the pattern of cytotoxicity produced against 3 myeloblasts studied in the fresh and frozen state. The KDC of 34 sera for one myeloblast was compared using fresh and frozen myeloblasts as targets. An identical pattern of positive, possible positive and negative cytotoxic results was seen in both cases. Fig. 5 shows a comparison of the cytotoxicity of 3 active sera for fresh and frozen myeloblasts. Allowing for a lower baseline release from the fresh myeloblasts, the pattern is similar in both situations. In one case where there was a five-fold difference in titre, the frozen myeloblast was more sensitive. The cytotoxicity of 7 selected sera was compared for fresh and frozen myeloblasts of another 2 patients. Again, no difference in susceptibility to cytotoxicity was seen, apart from an increased baseline release from frozen cells. It therefore seems unlikely that the use of frozen cells has prevented recognition of cytotoxicity in this system. The properties of antibody and myeloblasts appeared to be retained for periods of several months. This was shown by repeating assays with the same serum sample and batch of myeloblasts at intervals of one year.
4. Activity of sera against a panel of blood lymphocytes from healthy donors To test the specificity of the activity of these sera, 7 sera cytotoxic to myeloblasts were selected, and tested for KDC activity against the peripheral blood lymphocytes of 5 healthy volunteers. In Fig. 6 the cytotoxic activity observed is compared with that of the same sera for myeloblasts. The sera proved to be equally active against lymphocytes and myeloblasts, showing that there was considerable activity against normal allogeneic antigens. This activity might overlap with most or possibly all of the antibody-induced cytotoxicity against allogeneic leukaemic myeloblasts. The remaining experiments were designed to see if any of the cytotoxic activity in these sera was myeloblast specific. (Currie, 1972) . An exception to this discouraging picture was the report by Powles et al. (1973) Serum of patients treated with this type of immunotherapy contain antibodies capable of inducing both complement-and K-cell-dependent lysis of allogeneic myeloblasts. Complement-dependent antibody occurs both early and late in the course of immunotherapy, whereas KDC antibody appears with increased frequency with increased duration of immunotherapy and number of immunizing myeloblasts used. Some of the difference in this pattern of occurrence may relate to the fact that complementdependent cytotoxicity can be induced by both IgM and IgG, while KDC is generally only induced by IgG.
The detected activity did not appear to be directed against an antigen universally present on, and specific to myeloblasts. No serum was active against all of the panel of 5 myeloblasts used, a similar incidence of cytotoxicity of the same sera to normal peripheral blood lymphocytes was seen, and activity against autologous myeloblasts was not seen.
What then is the nature of the observed activity ? Klouda et al. (1975) have demonstrated cytotoxicity to lymphocytes in the serum of immunotherapy patients. These antibodies appeared to be directed against HLA antigens. Hersey et al. (1973) recognized that the activity they detected might be of this type. The findings presented here would be compatible with the hypothesis that the cytotoxicity observed was directed at HLA antigens present on the immunizing and " panel " myeloblasts and on the normal lymphocytes used as targets. It has been suggested that under certain circumstances allogeneic antigens may appear on tumour cells, which are not normally present on the cells of the tumour's host (Garrido, Schirrmacher and Festenstein, 1976) . This has been used as an explanation of successful protection against tumour growth in some animal systems, by immunization with normal allogeneic tissue (Invernizzi and Parmiani, 1975) . This work does not suggest that immunotherapy used here has induced antibody to HLA antigens on autologous tumour cells.
The frequent finding of non-tumourspecific cytotoxicity against allogeneic myeloblasts emphasizes the need for cautious interpretation of the results of tests for tumour-specific cytotoxicity, when allogeneic tumour cells or cell culture lines are used as targets.
The work described here is limited, in that it could only have demonstrated a tumour-specific antigen capable of initiating the production of an antibody which can induce complement-or K-cell-mediated cytotoxicity. It cannot exclude the presence of tumour-specific antigens, on myeloblasts, which under the conditions of immunotherapy used do not induce cytotoxic antibody, but could be detected by an alternative method such as indirect immunofluorescence.
